[1] Blackman HJ, Yoneda C, Dawson CR, et al. Antibiotic susceptibility of Chlamydia trachomatis. Antimicrob Agents Chemother,1977, 12:673-637. [2] Stamm WE, Tam M, Koester M, et al. Detection of Chlamydia trachomatis inclusions in Mccoy cell cultures with fluoresceinconjugated monoclonal antibodies.J Clin Microbiol, 1983, 17:666-668. [3] Cevenini R, Donati M, Sambri V, et al.Enzyme-linked immunosorbent assay for the in-vitro detection of sensitivity of Chlamydia trachomatis to antimicrobialdrugs. J Antimicrob Chemother, 1987, 20:677-684. [4] Cross NA, Kellock DJ, Kinghorn GR, et al.Antimicrobial susceptibility testing ofChlamydia trachomatis using a reverse transcriptase PCR-based method. Antimicrob Agents Chemother, 1999, 43:23112313. [5] Scheibel JH, Kristensen JK, Hentzer B, et al. Treatment of chlamydial urethritis in men and Chlamydia trachomatis-positive female partners: comparison of erythromycin and tetracycline in treatment courses of one week. Sex Transm Dis,1982, 9:128-131. [6] Jacobson GF, Autry AM, Kirby RS, et al.A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. Am J Obstet Gynecol, 2001, 184:1352-1354. [7] Hueston WJ, Lenhart JG. A decision analysis to guide antibiotic selection for Chlamydia infection during pregnancy.Arch Fam Med, 1997, 6:551-555. [8] Robinson AJ, Ridgway GL. Concurrent gonococcal and chlamydial infection: how best to treat. Drugs, 2000, 59:801-813. [9] Skerk V, Schonwald S, Strapac Z, et al.Duration of clinical symptoms in female patients with acute urethral syndrome caused by Chlamydia trachomatis treated with azithromycin or doxycycline. J Chemother, 2001, 13:176-181. [10] Jones RB, Van der Pol B, Johnson RB.Susceptibility of Chlamydia trachomatis to trovafloxacin. J Antimicrob Chemother,1997, 39 Suppl B:63-65. [11] Malay S, Roblin PM, Reznik T, et al. In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother,2002, 46:517-518. [12] Horner PJ, Cain D, McClure M, et al. Association of antibodies to Chlamydia trachomatis heat-shock protein 60 kD with chronic nongonococcal urethritis. Clin Infect Dis, 1997, 24:653-660. [13] Somani J, Bhullar VB, Workowski KA, et al.Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure.J Infect Dis, 2000, 181:14211427. [14] Dessus-Babus S, Bebear CM, Charron A,et al. Sequencing of gyrase and topoisomerase Ⅳ quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro. Antimicrob Agents Chemother, 1998, 42:2474-2481. [15] Lenart J, Andersen AA,Rockey DD.Growth and development of tetracyclineresistant Chlamydia suis.Antimicrob Agents Chemother, 2001, 45:2198-2203. [16] Lefevre JC, Lepargneor JP. Comparative in vitro susceptibility of a tetracycline-resistant Chlamydia trachomatis strain isolated in Toulouse (France). Sex Transm Dis,1998, 25:350-352. [17] Centres for Diseases Control and Prevention. 2002 Guidelines for treatment of sexually transmitted diseases. MMWR, 2002,51(No.RR-6) :32-35. |